Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients

Speciality: Oncology

Description:

Welcome to this insightful discussion with Dr. Parveen Jain on the transformative role of CDK4/6 inhibitors in improving outcomes for HR+/HER2- metastatic breast cancer (mBC) patients. In this video, Dr. Jain delves into the significant clinical advancements brought about by these targeted therapies, particularly their impact on extending progression-free survival (PFS) and overall survival (OS). With extensive research and real-world evidence supporting their efficacy, CDK4/6 inhibitors have become a cornerstone in the management of advanced hormone receptor-positive breast cancer.

Dr. Jain explains how CDK4/6 inhibitors, such as palbociclib, ribociclib, and abemaciclib, work by blocking cell cycle progression, thereby delaying disease progression and improving survival rates. Clinical trials like MONALEESA, PALOMA, and MONARCH have demonstrated substantial benefits, with some studies showing not only prolonged PFS but also a notable extension in OS. These findings have reshaped treatment paradigms, offering hope to patients with HR+/HER2- mBC.

Stay tuned as Dr. Parveen Jain breaks down the latest data, patient selection criteria, and future directions in CDK4/6 inhibitor therapy. Don’t miss this comprehensive overview that highlights how these innovative treatments are changing the landscape of metastatic breast cancer care. Be sure to watch till the end and subscribe for more expert insights on cutting-edge oncology advancements!

See More Webinars @ Hidoc Webinars